Corbus CEO, Yuval Cohen, Ph.D., spoke with BiotechTV's Brad Loncar about Corbus' pipeline, including the potential of CRB-701, a next-generation #AntibodyDrugConjugate targeting expression of Nectin-4 and the Company's development of CRB-913 for the treatment of #obesity. Watch the full interview here: https://bit.ly/3JZlRUT #RBCHealthcare
𝐑𝐁𝐂 𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞: Corbus Pharmaceuticals CEO Yuval Cohen on nectin-4 ADCs, integrin biology, and an alternative to GLPs for weight loss. Full video: https://lnkd.in/eJu6E5ha
CEO, GBAC | BoardroomEducation.com Accreds | WEF Thought Leader | Board, Audit Committee | Qualified Investor | AI/Cloud Gov | Public Co. Board Exp; NYSE, NASDAQ, TSX, LSE. ASX
3moGreat listening to you Yuval Cohen , #RBCHealthcare